We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+7.49%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$9.72B
AUM Growth
+$589M
Cap. Flow
-$37.2M
Cap. Flow %
-0.38%
Top 10 Hldgs %
31.39%
Holding
419
New
23
Increased
181
Reduced
152
Closed
9

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$48.3M
2
ABBV icon
AbbVie
ABBV
+$40.8M
3
SRE icon
Sempra
SRE
+$23.4M
4
CVX icon
Chevron
CVX
+$21.9M
5
HPQ icon
HP
HPQ
+$21.2M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$72M
2
ENB icon
Enbridge
ENB
+$61.3M
3
MSFT icon
Microsoft
MSFT
+$45.4M
4
KMB icon
Kimberly-Clark
KMB
+$42.1M
5
VIRT icon
Virtu Financial
VIRT
+$10.4M

Sector Composition

Rank Sector Weight
1 Technology 17.92%
2 Healthcare 16.37%
3 Financials 13.94%
4 Industrials 11.5%
5 Consumer Staples 11.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EEM icon
276
iShares MSCI Emerging Markets ETF
EEM
$28.8B
$1M 0.01%
21,310
+4,500
+27% +$208K
GBCI icon
277
Glacier Bancorp
GBCI
$6.42B
$981K 0.01%
24,898
+495
+2% +$18.8K
ESRX
278
DELISTED
Express Scripts Holding Company
ESRX
$972K 0.01%
13,024
-300
-2% -$19.2K
MEDP icon
279
Medpace
MEDP
$16.1B
$959K 0.01%
26,435
+435
+2% +$15.2K
EPP icon
280
iShares MSCI Pacific ex Japan ETF
EPP
$2.22B
$954K 0.01%
19,948
-300
-1% -$14.2K
PFM icon
281
Invesco Dividend Achievers ETF
PFM
$791M
$950K 0.01%
35,899
-2,850
-7% -$72.8K
HBAN icon
282
Huntington Bancshares
HBAN
$34.4B
$935K 0.01%
64,190
+1,200
+2% +$16.9K
SGC icon
283
Superior Group of Companies
SGC
$185M
$927K 0.01%
34,695
+780
+2% +$19.1K
DHR icon
284
Danaher
DHR
$137B
$924K 0.01%
11,229
+592
+6% +$48.1K
COLM icon
285
Columbia Sportswear
COLM
$3.04B
$904K 0.01%
12,585
+245
+2% +$16.1K
LHX icon
286
L3Harris
LHX
$51.6B
$884K 0.01%
6,243
-7,984
-56% -$1.11M
SAP icon
287
SAP
SAP
$212B
$863K 0.01%
7,685
BA icon
288
Boeing
BA
$171B
$862K 0.01%
2,925
+4
+0.1% +$1.08K
POWI icon
289
Power Integrations
POWI
$3.38B
$830K 0.01%
22,582
+390
+2% +$14.9K
TMO icon
290
Thermo Fisher Scientific
TMO
$213B
$821K 0.01%
4,324
-36
-0.8% -$6.9K
HDB icon
291
HDFC Bank
HDB
$123B
$798K 0.01%
31,400
ABAX
292
DELISTED
Abaxis Inc
ABAX
$795K 0.01%
16,058
-8,565
-35% -$409K
TEL icon
293
TE Connectivity
TEL
$59.6B
$765K 0.01%
8,044
EXR icon
294
Extra Space Storage
EXR
$31.3B
$762K 0.01%
8,712
CB icon
295
Chubb
CB
$135B
$759K 0.01%
5,194
+180
+4% +$26.9K
CSX icon
296
CSX Corp
CSX
$93.4B
$755K 0.01%
41,175
+16,200
+65% +$287K
IFF icon
297
International Flavors & Fragrances
IFF
$20.2B
$712K 0.01%
4,667
+15
+0.3% +$2.25K
SI
298
DELISTED
SIEMENS AKTIENGESELLSCHAFT ADS
SI
$712K 0.01%
10,275
VYM icon
299
Vanguard High Dividend Yield ETF
VYM
$80.9B
$704K 0.01%
8,219
+1,474
+22% +$123K
QTS
300
DELISTED
QTS REALTY TRUST, INC.
QTS
$701K 0.01%
+12,950
New +$722K

Similar funds

Bahl & Gaynor's Q4 2017 Portfolio in Review

As of Q4 2017, Bahl & Gaynor held 419 positions worth $9.72B, up 6.4% from $9.13B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bahl & Gaynor's Q4 2017 filing shows 23 new, 181 increased, 152 reduced and 9 closed positions. Its largest new stake was iShares Core High Dividend ETF: 534,010 shares worth $9.63M. The largest sale was Merck, an estimated $72M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Bahl & Gaynor's largest Q4 2017 buy was iShares Core High Dividend ETF: 534,010 shares worth $9.63M.
  • Bahl & Gaynor added most to Amgen in Q4 2017, an estimated $48.3M increase.
  • Bahl & Gaynor's biggest Q4 2017 reduction was Merck, cutting an estimated $72M.
  • Bahl & Gaynor fully exited Virtu Financial in Q4 2017, selling an estimated $10.4M.
  • Bahl & Gaynor's ten largest holdings make up 31% of its $9.72B portfolio in Q4 2017.
  • Bahl & Gaynor opened 23 new positions and closed 9 in Q4 2017.
  • Bahl & Gaynor's portfolio value rose 6.4% quarter-over-quarter to $9.72B.

Based on Bahl & Gaynor's 13F filing for Q4 2017, filed 13 Feb 2018.